



BIOHEART

Media Contact: Alexandra Curbelo
Wragg & Casas Public Relations
1221 Brickell Avenue, Suite 730
Miami, Fl. 33131
305-372-1234 ex.108
Email: acurbelo@wraggcasas.com

For Immediate Release

**BIOHEART ANNOUNCES AGREEMENT WITH GLOBAL STEM
CELL GROUP TO PROVIDE BIOHEART THERAPIES AND
TRAINING**

Sunrise, FL —November 4, 2013 – [Bioheart, Inc.](#) (BHRT.OB,) a biotech company focused on the discovery, development and commercialization of autologous cell therapies to treat cardiovascular disease, has announced an agreement with [Global Stem Cells Group, Inc.](#) of Miami to provide Bioheart therapies and products to its worldwide network of physicians and qualified patients.

The agreement between the two companies also provides an opportunity for Global Stem Cells Group to expand the network by training additional physicians in Bioheart’s regenerative medicine techniques while contributing to the development and commercialization of Bioheart’s [regenerative medicine products](#).

“Combining the large network of physicians at Global Stem Cells Group with currently available Bioheart therapies and products will help strengthen and broaden our program. We are looking forward to working with GSCG to expand our therapies globally and offering new therapies to patients who suffer from debilitating conditions,” said Mike Tomas, CEO of Bioheart, Inc.

Global Stem Cells Group, a biotech company specializing in adult stem cell research, therapies and products, is comprised of six cutting-edge stem cell treatment companies each with a distinct mission based on research and proven technology.

The Global Stem Cells Group offers a sophisticated global network of physicians to train other physicians in these innovative cellular therapies and techniques, and to provide them to patients from all corners of the world.

“We’re very pleased to be working with Bioheart to expand their therapies globally,” says Global Stem Cells Group Founder and COO Ricardo de Cubas. “Our companies are both focused on delivering cellular therapies to patients everywhere who suffer from debilitating medical conditions and disease, and that makes this collaboration a natural one.”

About Bioheart, Inc

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About the Global Stem Cell Group

[Global Stem Cells Group, Inc.](http://www.globalstemcellsgroup.com) is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

To learn more about Global Stem Cells Group, Inc., and for investor information, visit the [Global Stem Cell Group website](#), email bnovas@regenestem.com, or call 305-224-1858.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2013.